Biotech’s IPO out­look for the rest of the year sours in wake of war, broad­er in­dus­try strug­gles

For­get IPOs. Biotech in­sid­ers ex­pect to see a hand­ful of re­verse merg­ers be­fore the end of the year, sim­i­lar to Wednes­day’s hand­shake be­tween Nas­daq-list­ed Graphite Bio and eye drop mak­er Lenz Ther­a­peu­tics, and Thurs­day’s deal be­tween Ho­mol­o­gy Med­i­cines and Q32 Bio.

“It wasn’t ur­gent to us. It’s not that we had to do some­thing,” Lenz Ther­a­peu­tics CEO Eef Schim­melpen­nink told End­points News, say­ing the com­pa­ny had enough mon­ey to car­ry it to 2025 with­out the deal. “This was just the right thing with the right in­vestors at the right mo­ment.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER